What is the diagnostic algorithm for sarcoma?

Diagnostic Algorithm for Sarcoma

All patients with suspected sarcoma—defined as any unexplained deep soft tissue mass or superficial lesion ≥5 cm—must be immediately referred to a specialized sarcoma reference center before any biopsy or surgical intervention. 1, 2, 3, 4

Initial Clinical Assessment

Focus your history on:

• Pain characteristics: Persistent non-mechanical bone pain, especially nocturnal pain, suggests bone sarcoma 5
• Duration: Any solid limb mass present >4 weeks requires diagnostic evaluation 6
• Age-specific considerations:
  • <5 years: Consider metastatic neuroblastoma or Langerhans cell histiocytosis

  • 5 years: Primary bone sarcoma more likely

  • 40 years: Bone metastases and myeloma most common 5

• Prior radiation exposure: Significant risk factor for sarcoma development 7

Physical examination should document tumor size, depth (superficial vs. deep to fascia), consistency, mobility, and regional lymph nodes 8.

Imaging Sequence

Step 1: Initial Imaging

• Soft tissue sarcomas: MRI is the primary modality for extremity, pelvis, and trunk lesions—image the entire compartment with adjacent joints 5, 1, 2, 3
• Bone sarcomas: Begin with conventional radiographs in two planes 5, 8
• Retroperitoneal/visceral: CT scan is preferred (performance equivalent to MRI) 2, 3, 4

Step 2: Advanced Local Staging

If malignancy cannot be excluded:

• For bone lesions: Proceed to MRI of whole bone with adjacent joints 5, 8
• For soft tissue: CT may supplement MRI to visualize calcifications, periosteal bone formation, or cortical destruction 5, 8

Step 3: Systemic Staging (performed at reference center)

• Chest CT: Mandatory for all intermediate/high-grade tumors to detect pulmonary metastases 1, 3
• Abdomen/pelvis CT or MRI: Required for:
  • Myxoid liposarcoma (high risk of soft tissue metastases) 1, 3
  • Leiomyosarcoma, epithelioid sarcoma, angiosarcoma 3
  • High-grade lower extremity sarcomas 1
• Brain MRI: For alveolar soft part sarcoma, clear cell sarcoma, and angiosarcoma (high CNS metastasis risk) 3
• Regional lymph node assessment: For synovial sarcoma, clear cell sarcoma, angiosarcoma, epithelioid sarcoma 1

Biopsy Protocol (CRITICAL: Must be performed at sarcoma reference center)

The biopsy must be performed by the surgeon who will perform definitive resection or by a dedicated interventional radiologist within the reference center team 5, 8, 9, 2. This is non-negotiable—improper biopsy technique contaminates tissue planes and compromises limb salvage surgery.

Biopsy Technique:

1. Core needle biopsy (14-16G needles): Standard approach for most lesions 1, 2, 3, 4

   • Obtain 4-6 cores using image guidance
   • Use coaxial introducer for single skin entrance 3
   • Avoid necrotic areas 3

2. Excisional biopsy: Only for superficial lesions <3 cm 2, 4 or <5 cm 9

3. Open biopsy: Selected cases only, using longitudinal incision 5, 8

   • Biopsy tract must be planned for en bloc removal during definitive surgery
   • Consider tattooing the entrance point 9, 2

4. Fine needle aspiration: NOT recommended except in specialized centers with specific expertise 1, 9, 2

Tissue Handling:

• Fix in 4% buffered formalin (NOT Bouin fixative—prevents molecular analysis) 9, 2
• Collect fresh snap-frozen tissue for molecular testing 1, 2, 4
• Send samples for microbiological culture if osteomyelitis is differential 5, 8

Pathological Diagnosis

Central pathology review by an expert sarcoma pathologist is mandatory 3—discrepancy rates between community and expert diagnosis range from 8-16% 4.

Required elements:

• Histological classification: Per WHO 2020 classification 4
• Grading: FNCLCC system (based on differentiation, necrosis, mitotic rate) 9, 2, 3
• Molecular testing: When morphology and immunohistochemistry insufficient for precise diagnosis 3

Common Pitfalls to Avoid

1. Never perform excisional biopsy on deep lesions or large superficial masses—this contaminates multiple tissue compartments and compromises subsequent surgery 8

2. Do not use frozen section for immediate diagnosis—it prevents complete pathological assessment, especially when neoadjuvant therapy is planned 9, 2

3. Biopsy may underestimate tumor grade—use radiological features (necrosis on imaging, FDG-PET uptake) to supplement pathological grading when planning neoadjuvant therapy 9, 2

4. Recent trauma does not rule out malignancy—proceed with appropriate diagnostic workup 8

5. For retroperitoneal masses: Always obtain preoperative biopsy if neoadjuvant therapy considered or if suspicion exists for lymphoma or germ cell tumor (to avoid inappropriate major resection) 10

Multidisciplinary Tumor Board Review

All suspected sarcomas must be discussed at weekly multidisciplinary tumor board before definitive treatment 3, 4. The board should include surgical oncology, medical oncology, radiation oncology, radiology, and pathology expertise specific to sarcomas.